Supernus Pharmaceuticals, Inc. News

Supernus Pharmaceuticals (SUPN) After Its Indivior Merger Looks Undervalued

Cantor Fitzgerald Maintains Overweight on Supernus, Raises Price Target to $87

Supernus Pharmaceuticals (SUPN) Stock May Be Undervalued After ONAPGO Exclusivity

What Changes For Supernus Pharmaceuticals (SUPN) After Its Nasdaq Delisting And Merger?

Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger

Supernus (SUPN) Q3 2026 Earnings Call Transcript

Supernus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Supernus Pharmaceuticals Q3 Earnings Call Highlights

Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Q3 Estimates and Raises Outlook as Indivior Merger Nears

Supernus: Q3 Earnings Snapshot

Supernus Pharmaceuticals (NASDAQ:SUPN) delivers impressive Q3 2026, full-year sales guidance is optimistic

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript

Supernus Announces Third Quarter 2026 Financial Results

Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript

Supernus Pharmaceuticals Raises FY2026 Sales Guidance from $860.000M-$890.000M to $875.000M-$900.000M vs $877.738M Est

Supernus Pharmaceuticals Q3 EPS $0.35 Beats $0.02 Estimate, Sales $226.771M Beat $215.917M Estimate

Supernus Pharmaceuticals earnings: what to look for from SUPN

Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree® for ‘Ms. Represented’ Campaign

MSG Rangers To Replace Arbor Realty Trust In The S&P SmallCap 600 Effective On October 27; Huron Consulting Group To Replace Supernus Pharmaceuticals In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Monday, November 2